Cyclin D-dependent kinases, INK4 inhibitors and cancer

被引:593
作者
Ortega, S
Malumbres, M
Barbacid, M
机构
[1] Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid 28029, Spain
[2] CSIC, Natl Biotechnol Ctr, E-28049 Madrid, Spain
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2002年 / 1602卷 / 01期
关键词
cyclin D-Cdk4,6/INK4/Rb/E2F pathway; cancer therapy; Cdk inhibitors;
D O I
10.1016/S0304-419X(02)00037-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Cyclin D-Cdk4,6/lNK4/Rb/E2F pathway plays a key role in controlling cell growth by integrating multiple mitogenic and antimitogenic stimuli. The components of this pathway are gene families with a high level of structural and functional redundancy and are expressed in an overlapping fashion in most tissues and cell types. Using classical transgenic technology as well as gene-targeting in ES cells, a series of mouse models have been developed to study the in vivo function of individual components of this pathway in both normal homeostasis and tumor development. These models have proven to be useful to define specific as well as redundant roles among members of these cell cycle regulatory gene families. This pathway is deregulated in the vast majority of human tumors by genetic and epigenetic alterations that target at least some of its key members such as Cyclin D1, Cdk4, INK4a and INK4b, pRb etc. As a consequence, some of these molecules are currently being considered as targets for cancer therapy, and several novel molecules, such as Cdk inhibitors, are under development as potential anti-cancer drugs. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:73 / 87
页数:15
相关论文
共 126 条
  • [51] Limited overlapping roles of p15INK4b and p18INK4c cell cycle inhibitors in proliferation and tumorigenesis
    Latres, E
    Malumbres, M
    Sotillo, R
    Martín, J
    Ortega, S
    Martín-Caballero, J
    Flores, JM
    Cordón-Cardo, C
    Barbacid, M
    [J]. EMBO JOURNAL, 2000, 19 (13) : 3496 - 3506
  • [52] MICE DEFICIENT FOR RB ARE NONVIABLE AND SHOW DEFECTS IN NEUROGENESIS AND HEMATOPOIESIS
    LEE, EYHP
    CHANG, CY
    HU, NP
    WANG, YCJ
    LAI, CC
    HERRUP, K
    LEE, WH
    BRADLEY, A
    [J]. NATURE, 1992, 359 (6393) : 288 - 294
  • [53] Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway
    Lee, RJ
    Albanese, C
    Fu, MF
    D'Amico, M
    Lin, B
    Watanabe, G
    Haines, GK
    Siegel, PM
    Hung, MC
    Yarden, Y
    Horowitz, JM
    Muller, WJ
    Pestell, RG
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (02) : 672 - 683
  • [54] Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-Cell lymphomas: Comparison with CD56-negative peripheral T-cell lymphomas
    Lien, HC
    Lin, CW
    Huang, PH
    Chang, ML
    Hsu, SM
    [J]. LABORATORY INVESTIGATION, 2000, 80 (06) : 893 - 900
  • [55] LOIS AF, 1995, CANCER RES, V55, P4010
  • [56] Cyclin D1 in parathyroid disease
    Mallya, SM
    Arnold, A
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 : D367 - D371
  • [57] Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors
    Malumbres, M
    Ortega, S
    Barbacid, M
    [J]. BIOLOGICAL CHEMISTRY, 2000, 381 (9-10) : 827 - 838
  • [58] Cellular response to oncogenic Ras involves induction of the Cdk4 and Cdk6 inhibitor p15INK4b
    Malumbres, M
    Perez de Castro, I
    Hernández, MI
    Jiménez, M
    Corral, T
    Pellicer, A
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) : 2915 - 2925
  • [59] Inactivation of the cyclin-dependent kinase inhibitor p15(INK4b) by deletion and de novo methylation with independence of p16(INK4 alpha) alterations in murine primary T-cell lymphomas
    Malumbres, M
    Perez de Castro, I
    Santos, J
    Melendez, B
    Mangues, R
    Serrano, M
    Pellicer, A
    FernandezPiqueras, J
    [J]. ONCOGENE, 1997, 14 (11) : 1361 - 1370
  • [60] To cycle or not to cycle: A critical decision in cancer
    Malumbres, M
    Barbacid, M
    [J]. NATURE REVIEWS CANCER, 2001, 1 (03) : 222 - 231